Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1508-1514

  Kaga, Chiaki ^a   Takagi, Akimitsu ^a   Kano, Mitsuyoshi ^a   Kado, Shoichi ^a   Kato, Ikuo ^a   Sakai, Masashi ^a   Miyazaki, Kouji ^a   Nanno, Masanobu ^a   Ishikawa, Fumiyasu ^a   Ohashi, Yasuo ^b   Toi, Masakazu ^c  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ESTROGEN RECEPTOR ALPHA; ISOFLAVONE DERIVATIVE; KI 67 ANTIGEN; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DIET THERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; LACTOBACILLUS CASEI; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; SOYBEAN MILK; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; FEMALE; IMIDAZOLES; KI-67 ANTIGEN; LACTOBACILLUS CASEI; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SIZE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SOY MILK; SPLEEN;

EID: 84888022628     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12268     Document Type: Article

References (50)

1. Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg 2008; 32: 2578-85.
2. Hirabayashi Y, Zhang M. Comparison of time trends in breast cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 2009; 39: 411-2.
3. Shin HR, Boniol M, Joubert C et al. Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci 2010; 101: 1241-6.
4. Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J 2004; 3: 19.
5. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 2003; 95: 906-13.
6. Molteni A, Brizio-Molteni L, Persky V. In vitro hormonal effects of soybean isoflavones. J Nutr 1995; 125: 751S-6.
7. Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5.
8. Su SJ, Yeh TM, Chuang WJ et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 2005; 69: 307-18.
9. Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J Natl Cancer Inst 1998; 90: 381-8.
10. Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 2004; 68: 1171-85.
11. Kushi LH, Doyle C, McCullough M et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62: 30-67.
12. Rowland IR, Rumney CJ, Coutts JT, Lievense LC. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281-5.
13. Marotta F, Naito Y, Minelli E, Tajiri H, Bertuccelli J, Wu CC. Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study. Hepatogastroenterology 2003; 50: 1914-8.
14. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T. Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. Med Microbiol Immunol 1999; 188: 111-6.
15. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 2001; 22: 599-605.
16. Takagi A, Ikemura H, Matsuzaki T et al. Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. J Gastroenterol 2008; 43: 661-9.
17. Yamazaki K, Tsunoda A, Sibusawa M et al. The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. Oncol Rep 2000; 7: 977-82.
18. Matsuguchi T, Takagi A, Matsuzaki T et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol 2003; 10: 259-66.
19. Takahashi T, Kushiro A, Nomoto K et al. Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2. J Urol 2001; 166: 2506-11.
20. Ohashi Y, Nakai S, Tsukamoto T et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 2002; 68: 273-80.
21. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 1995; 27: 104-9.
22. Naito S, Koga H, Yamaguchi A et al. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol 2008; 179: 485-90.
23. Ishikawa H, Akedo I, Otani T et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116: 762-7.
24. Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993; 73: 173-9.
25. Kato K, Mizuno S, Umesaki Y et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-41.
26. Scharlau D, Borowicki A, Habermann N et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 2009; 682: 39-53.
27. Toi M, Hirota S, Tomotaki A et al. Probiotic beverage with soy isoflavone consumption for breast cancer prevention: a case-control study. Curr Nutr Food Sci 2013; 9: 194-200.
28. Ohta T, Nakatsugi S, Watanabe K et al. Inhibitory effects of Bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones. Carcinogenesis 2000; 21: 937-1.
29. Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr 2006; 136: 2291-6.
30. Nakatsugi S, Ohta T, Kawamori T et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000; 91: 886-92.
31. Nozawa H, Nakao W, Takata J, Arimoto-Kobayashi S, Kondo K. Inhibition of PhIP-induced mammary carcinogenesis in female rats by ingestion of freeze-dried beer. Cancer Lett 2006; 235: 121-9.
32. Tayek JA, Istfan NW, Jones CT, Hamawy KJ, Bistrian BR, Blackburn GL. Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body protein synthesis and growth rate in the cancer-bearing rat. Cancer Res 1986; 46: 5649-54.
33. Russo J, Russo IH, Rogers AE, van Zwieten MJ, Gusterson B. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the mammary gland. IARC Sci Publ 1990; 99: 47-78.
34. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48: 674-82.
35. Macinnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2117-25.
36. Velasquez MT, Bhathena SJ. Role of dietary soy protein in obesity. Int J Med Sci 2007; 4: 72-82.
37. Satsu M, Mizutani T, Mikubo A, Shimizu K. Study of the regulation of drug metabolizing enzymes by soybean ingredients in intestinal epithelial cells. Soy Protein Res Jpn 2010; 13: 79-84.
38. Forghani P, Khorramizadeh MR, Waller EK. Natural suppressor cells; past, present and future. Front Biosci (Elite Ed) 2012; 4: 1237-45.
39. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 900-9.
40. Tu SP, Jin H, Shi JD et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 2012; 5: 205-15.
41. Qiu C, Shan L, Yu M, Snyderwine EG. Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Carcinogenesis 2005; 26: 763-9.
42. Diel P, Olff S, Schmidt S, Michna H. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7. Planta Med 2001; 67: 510-4.
43. Sathyamoorthy N, Wang TT. Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells. Eur J Cancer 1997; 33: 2384-9.
44. Cohen LA, Crespin JS, Wolper C et al. Soy isoflavone intake and estrogen excretion patterns in young women: effect of probiotic administration. In Vivo 2007; 21: 507-12.
45. Toi M, Saji S, Masuda N et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 2011; 102: 858-65.
46. Khan SA, Chatterton RT, Michel N et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res 2012; 5: 309-19.
47. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
48. Matsumoto S, Hara T, Hori T et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140: 417-26.
49. Matsumoto S, Hara T, Nagaoka M et al. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Immunology 2009; 128: e170-80.
50. Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 2001; 30: 1293-1302.